FTC shows an interest
Federal Trade Commission filed a "friend of the court" brief in the Bristol/ABI/Ivax case indicating that the agency is investigating the terms of Bristol's licensing agreement for the ABI patent. The patent, covering a Cremophor-free formulation of paclitaxel, was listed by Bristol in mid-August (1"The Pink Sheet" Aug. 21, p. 3)
You may also be interested in...
Bristol-Myers Squibb's latest extension to the exclusivity for Taxol depends on continued rulings against the company in patent litigation in the Los Angeles federal court.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials